WO1996020215A3 - Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases - Google Patents

Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases Download PDF

Info

Publication number
WO1996020215A3
WO1996020215A3 PCT/EP1995/005164 EP9505164W WO9620215A3 WO 1996020215 A3 WO1996020215 A3 WO 1996020215A3 EP 9505164 W EP9505164 W EP 9505164W WO 9620215 A3 WO9620215 A3 WO 9620215A3
Authority
WO
WIPO (PCT)
Prior art keywords
mhc
molecules
binding
prevention
interaction
Prior art date
Application number
PCT/EP1995/005164
Other languages
French (fr)
Other versions
WO1996020215A2 (en
Inventor
Roger Pascal Lauener
Original Assignee
Om Lab Sa
Deutsche Om Arzneimittel Gmbh
Roger Pascal Lauener
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Lab Sa, Deutsche Om Arzneimittel Gmbh, Roger Pascal Lauener filed Critical Om Lab Sa
Priority to SK806-97A priority Critical patent/SK80697A3/en
Priority to JP8520220A priority patent/JPH10511652A/en
Priority to PL95320922A priority patent/PL320922A1/en
Priority to EP95942207A priority patent/EP0800534A2/en
Priority to AU43476/96A priority patent/AU4347696A/en
Priority to BR9510554A priority patent/BR9510554A/en
Publication of WO1996020215A2 publication Critical patent/WO1996020215A2/en
Publication of WO1996020215A3 publication Critical patent/WO1996020215A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention relates to MHC-II binding and/or MHC-II mimicking molecules for use in interfering in the interaction between an activation stimulus for MHC-II bearing cells, such as phagocytes and cell-bound MHC-II molecules, in the interaction between lipopolysaccharide (LPS) or LPS in a complex with other molecules, such as CD14 and LBP, and cell-bound MHC-II molecules, or in the interaction between products from Gram-positive bacteria or complexes of products from Gram-positive bacteria with molecules such as CD14, and cell-bound MHC-II molecules. The MHC-II binding molecule may be any anti-MHC-II antibody or fragment thereof, or any molecule derived from such an antibody such as humanized, bispecific or other engineered molecules and the like. The MHC-II binding molecule may be selected from the group consisting of CD14, fragments thereof, modified versions thereof, or peptides having MHC-II binding properties.
PCT/EP1995/005164 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases WO1996020215A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SK806-97A SK80697A3 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding molecules
JP8520220A JPH10511652A (en) 1994-12-23 1995-12-27 Use of MHC-II binding and / or MHC-II mimetic molecules for the prevention and / or treatment of inflammatory diseases
PL95320922A PL320922A1 (en) 1994-12-23 1995-12-27 Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
EP95942207A EP0800534A2 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
AU43476/96A AU4347696A (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
BR9510554A BR9510554A (en) 1994-12-23 1995-12-27 Use of mch-ii binding molecules and / or imitation molecules for the prevention and / or treatment of inflammatory diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203755 1994-12-23
EP94203755.7 1994-12-23

Publications (2)

Publication Number Publication Date
WO1996020215A2 WO1996020215A2 (en) 1996-07-04
WO1996020215A3 true WO1996020215A3 (en) 1996-10-10

Family

ID=8217495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/005164 WO1996020215A2 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Country Status (11)

Country Link
EP (1) EP0800534A2 (en)
JP (1) JPH10511652A (en)
CN (1) CN1171117A (en)
AU (1) AU4347696A (en)
BR (1) BR9510554A (en)
CA (1) CA2208233A1 (en)
CZ (1) CZ186897A3 (en)
HU (1) HUT77468A (en)
PL (1) PL320922A1 (en)
SK (1) SK80697A3 (en)
WO (1) WO1996020215A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) * 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
KR20040030786A (en) * 2001-07-02 2004-04-09 아임스코 리미티드 Therapeutic agent
JP2005532261A (en) * 2002-01-28 2005-10-27 エイムスコ・リミテッド Treatment
ES2232273B1 (en) * 2003-03-21 2006-07-16 Jose Manuel Fernandez-Real Lemos NEW THERAPEUTIC APPLICATIONS OF GLUCOPROTEIN CD14S.
EP1628530B8 (en) * 2003-05-15 2012-08-01 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790A2 (en) * 1981-06-25 1983-01-05 The Board Of Trustees Of The Leland Stanford Junior University Allele specific immunotherapeutic method and dosage form
EP0122814A2 (en) * 1983-04-18 1984-10-24 Bernard François Prof. Mach A method of cotransformation, cotransformed mouse cells producing at their surface human class II antigens and the use of those cells to generate mouse hybridomas that produce monoclonal antibodies to those antigens
EP0204522A2 (en) * 1985-05-30 1986-12-10 Genetic Systems Corporation Monoclonal antibody panel for histocompatibility typing
JPS63275526A (en) * 1987-05-03 1988-11-14 Hiroshi Okajima Hiv virus neutralizing antibody
WO1991012332A1 (en) * 1990-02-14 1991-08-22 Institut National De La Sante Et De La Recherche Medicale Monoclonal antibodies for recognizing a peptide linked to a major histocompatibility antigen
WO1992004908A1 (en) * 1990-09-14 1992-04-02 Imtox Privatinstitut Für Immunbiologische Forschung Gmbh Drug containing cd14
WO1993010220A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Soluble mhc molecules and their uses
WO1993019772A1 (en) * 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
CA2125871A1 (en) * 1992-10-15 1994-04-28 Keishi Miwa Process for preparing major histocompatibility antigen class ii protein and materials in which the same is bound
WO1994028025A1 (en) * 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
WO1994029451A2 (en) * 1993-06-16 1994-12-22 Celltech Limited Humanised antibodies

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790A2 (en) * 1981-06-25 1983-01-05 The Board Of Trustees Of The Leland Stanford Junior University Allele specific immunotherapeutic method and dosage form
EP0122814A2 (en) * 1983-04-18 1984-10-24 Bernard François Prof. Mach A method of cotransformation, cotransformed mouse cells producing at their surface human class II antigens and the use of those cells to generate mouse hybridomas that produce monoclonal antibodies to those antigens
EP0204522A2 (en) * 1985-05-30 1986-12-10 Genetic Systems Corporation Monoclonal antibody panel for histocompatibility typing
JPS63275526A (en) * 1987-05-03 1988-11-14 Hiroshi Okajima Hiv virus neutralizing antibody
WO1991012332A1 (en) * 1990-02-14 1991-08-22 Institut National De La Sante Et De La Recherche Medicale Monoclonal antibodies for recognizing a peptide linked to a major histocompatibility antigen
WO1992004908A1 (en) * 1990-09-14 1992-04-02 Imtox Privatinstitut Für Immunbiologische Forschung Gmbh Drug containing cd14
WO1993010220A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Soluble mhc molecules and their uses
WO1993019772A1 (en) * 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
CA2125871A1 (en) * 1992-10-15 1994-04-28 Keishi Miwa Process for preparing major histocompatibility antigen class ii protein and materials in which the same is bound
WO1994028025A1 (en) * 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
WO1994029451A2 (en) * 1993-06-16 1994-12-22 Celltech Limited Humanised antibodies

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 116, no. 17, 27 April 1992, Columbus, Ohio, US; abstract no. 171799k, page 641; column 171805; XP002001131 *
CHEMICAL ABSTRACTS, vol. 119, no. 1, 5 July 1993, Columbus, Ohio, US; abstract no. 6755w, SOOS ET AL.: "Identification of binding domains of the superantigen, toxic shock syndrome toxin-1, for class II MHC molecules" page 706; column 6757; XP002010928 *
DATABASE WPI Section Ch Week 8851, Derwent World Patents Index; Class B04, AN 365101, XP002001132 *
FISCHER ET AL.: "Binding of Staphylococcal enterotoxin A to HLA-DR on B cell lines", J. IMMUNOLOGY, vol. 142, no. 9, 1 May 1989 (1989-05-01), pages 3151 - 3157, XP000567839 *
FORSGREN ET AL.: "The role of I-A/E molecules in B lymphocyte activation : I. inhibition of lipopolysaccharide-induced responses by monoclonal antibodies", J. IMMUNOLOGY, vol. 133, no. 4, October 1984 (1984-10-01), pages 2104 - 2110, XP000567848 *
GREY ET AL.: "Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocates to LPS, IFN-gamma, or phorbol ester", J. IMMUNOLOGY, vol. 153, no. 8, 15 October 1994 (1994-10-15), pages 3664 - 3672, XP000567838 *
HAMANO ET AL.: "Direct involvement of surface I-A/E molecules during B-cell maturation using an antigen-specific B cell clone.", J. IMMUNOLOGY, vol. 144, no. 3, February 1990 (1990-02-01), pages 811 - 815, XP000567849 *
HARTWIG ET AL.: "Major histocompatibility complex class II binding site for Streptococcal pyrogenic (erythrogenic) toxin A", MED. MICROBIOL. IMMUNOL., vol. 183, no. 5, August 1994 (1994-08-01), pages 257 - 264, XP000578895 *
PONTZER ET AL.: "Agonist properties of a microbial superantigen peptide", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 193, no. 3, 30 June 1993 (1993-06-30), pages 1191 - 1197, XP000578187 *
PONTZER ET AL.: "Structural basis for differential binding of Staphylococcal enterotoxin A and toxic shock syndrome toxin-1 to class II major histocompatibility molecules", PROC. NATL ACAD. SCI., vol. 88, no. 1, 1 January 1991 (1991-01-01), pages 125 - 128, XP000578190 *
RUPPERT ET AL.: "IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency", IMMUNOBIOLOGY, vol. 182, no. 5, August 1991 (1991-08-01), pages 449 - 464, XP000578897 *
SCHOLL ET AL.: "Staphylococcal enterotoxin B and toxic shock syndrome toxin-1 bind to distinct sites on HLA-DR and HLA-DQ molecules", J. IMMUNOLOGY, vol. 143, no. 8, 15 October 1989 (1989-10-15), pages 2583 - 2588, XP000567847 *
SOOS, BIOCHEM. BIOPHYS. RES. COMMUN., vol. 191, no. 3, 1993, pages 1211 - 1217 *
STEIN ET AL.: "Anti-class II antibodies potentiate IgG2a production by lipopolysaccharide-stimulated B lymphocytes treated with prostaglandin E2 and IFN-gamma", J. IMMUNOLOGY, vol. 148, no. 12, 15 June 1992 (1992-06-15), pages 3943 - 3949, XP000567850 *
TORRES ET AL.: "Identification of an HIV-1 NEF peptide that binds to HLA class II antigens", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 200, no. 2, 29 April 1994 (1994-04-29), pages 1059 - 1065, XP000578181 *
UCHIYAMA ET AL.: "Involvement of HLA class II molecules in acquisistion of staphylococcal enterotoxin A-binding activity and acccessory cell activation of human T cells by related toxins in vascular endothelial cells", CLIN. EXP. IMMUNOL., vol. 87, no. 2, 1992, pages 322 - 328 *

Also Published As

Publication number Publication date
HUT77468A (en) 1998-05-28
PL320922A1 (en) 1997-11-10
WO1996020215A2 (en) 1996-07-04
CZ186897A3 (en) 1998-03-18
CA2208233A1 (en) 1996-07-04
SK80697A3 (en) 1997-12-10
AU4347696A (en) 1996-07-19
JPH10511652A (en) 1998-11-10
EP0800534A2 (en) 1997-10-15
BR9510554A (en) 1999-06-29
CN1171117A (en) 1998-01-21

Similar Documents

Publication Publication Date Title
WO2002061090A3 (en) Prokaryotically produced antibodies and uses thereof
WO1996020215A3 (en) Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
MXPA02000119A (en) Stacked static mixing elements.
WO2001098317A3 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
CA2223449A1 (en) Peptides and compounds that bind to the thrombopoietin receptor
GB9625640D0 (en) Biological products
WO2006087637A3 (en) Anti her2/neu antibody
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
CA2255826A1 (en) Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2005000897A3 (en) Antibodies against interleukin-22 and uses therefor
AU2836995A (en) Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB0411186D0 (en) Biological products
CA2182013A1 (en) Humanized antibodies against leukocyte adhesion molecule vla-4
DE69818557D1 (en) Anti-rot composition, process for its preparation and product treated with it
EP4218815A3 (en) Use of anti il-1beta antibodies
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
WO2002050122A3 (en) Means for the diagnosis and therapy of ctcl
AU7739796A (en) Azulenyl nitrone spin trapping agents, methods of making and using same
EP1412388A4 (en) Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin
EP1071443A4 (en) Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein bind to mhc class i and mhc class ii molecules, and uses thereof
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
EP1612557A3 (en) Binding surface
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95196985.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PV1997-1868

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2208233

Country of ref document: CA

Ref document number: 2208233

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019970704131

Country of ref document: KR

Ref document number: 80697

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 97-01172

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 1995942207

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 860145

Country of ref document: US

Date of ref document: 19970825

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995942207

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1997-1868

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019970704131

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1995942207

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1997-1868

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019970704131

Country of ref document: KR